The US Food and Drug Administration’s latest report to Congress on opening a regulatory pathway for using cannabidiols in products other than drugs makes clear that an additional $5m to support the work that House appropriators propose for the agency’s fiscal 2021 budget is needed.
While the FDA’s
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?